miRNA在肿瘤治疗相关心脏毒性中的研究进展

因心脏毒性的发生使抗肿瘤药物的临床使用受限。化疗、放疗、靶向治疗和免疫治疗均表现出不同频度和程度的心脏毒性，严重者可发生心力衰竭，危及患者生命。不同抗肿瘤治疗导致的心脏毒性作用机制复杂，氧化应激、DNA损伤、细胞凋亡等均可能参与。miRNA（microRNA）是细胞增殖、死亡、凋亡和分化的关键调控因子，其失调还与心脏重塑和心脏毒性密切相关。本文将对miRNAs可能参与不同肿瘤治疗所致心脏毒性发生的作用机制，及其在监测和治疗中的作用进行综述。 

Research progress of miRNA in cancer therapy induced cardiotoxicity

The cardiotoxicity associated with anti-cancer agents limits the clinical practice of cancer therapies. Asides traditional treatments such as chemotherapy and radiotherapy, new innovations in cancer treatments such as targeted therapy and immunotherapy are associated with different frequency and degrees of cardiotoxicity, which may result in heart failure and death. The mechanism underlying cancer therapy induced cardiotoxicity is still unclear. Oxidative stress, DNA damage, and apoptosis may be responsible for the differences in the cardiotoxicities of various cancer therapies. MicroRNAs (miRNAs) are key regulators of cell proliferation, cell death, and cell differentiation. MicroRNAs are also associated with cardiac remodeling and cardiotoxicity and play an important role in the development of a variety of cardiovascular diseases. This review will focus on the mechanisms by which different cancer therapies induce cardiotoxicity, especially those that involve miRNAs and the evaluation of miRNA in the monitoring and treatment of cancer therapy related cardiotoxicity.